D 2010

Determination of pCrkL level in chronic myeloid leukaemia cells using flow cytometry

ŠIMARA, Pavel, Stanislav STEJSKAL, Martina PETERKOVÁ, Irena KRONTORÁD KOUTNÁ, Zdeněk RÁČIL et. al.

Basic information

Original name

Determination of pCrkL level in chronic myeloid leukaemia cells using flow cytometry

Authors

ŠIMARA, Pavel (203 Czech Republic, belonging to the institution), Stanislav STEJSKAL (203 Czech Republic, belonging to the institution), Martina PETERKOVÁ (203 Czech Republic, belonging to the institution), Irena KRONTORÁD KOUTNÁ (203 Czech Republic, guarantor, belonging to the institution), Zdeněk RÁČIL (203 Czech Republic, belonging to the institution) and Jiří MAYER (203 Czech Republic, belonging to the institution)

Edition

Brno, Česká Republika, Advances in Molecular and Cancer Biology, 2010, p. 43-45, 3 pp. 2010

Publisher

muni PRESS

Other information

Language

English

Type of outcome

Stať ve sborníku

Field of Study

10601 Cell biology

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

Publication form

printed version "print"

RIV identification code

RIV/00216224:14330/10:00045382

Organization unit

Faculty of Informatics

ISBN

978-80-210-5312-0

Keywords in English

CML; imatinib; CD34+; pCrkL; flow cytometry

Tags

Reviewed
Změněno: 2/3/2018 10:23, Mgr. Pavel Šimara, Ph.D.

Abstract

V originále

Imatinib is a tyrosine kinase inhibitor nowadays used as a first line therapy for newly diagnosed chronic myeloid leukaemia (CML) patients. However, some of the patients relapse after initially good response. Therefore, reliable methods for predicting of the imatinib treatment response are sought. In our research we determine the level of phosphorylated CrkL protein, known as a substrate of Bcr-Abl, by flow cytometry. Its potential predictive value as a marker of imatinib treatment response will be assessed in the monuclear cells or CD34+ cells of peripheral blood samples of new CML patients.

Links

MSM0021622430, plan (intention)
Name: Funkční a molekulární charakteristiky nádorových a normálních kmenových buněk - identifikace cílů pro nová terapeutika a terapeutické strategie
Investor: Ministry of Education, Youth and Sports of the CR, Functional and molecular characteristics of cancer and normal stem cells - identification of targets for novel therapeutics and therapeutic strategies
2B06052, research and development project
Name: Vytipování markerů, screening a časná diagnostika nádorových onemocnění pomocí vysoce automatizovaného zpracování multidimenzionálních biomedicínských obrazů (Acronym: Biomarker)
Investor: Ministry of Education, Youth and Sports of the CR, Determination of markers, screening and early diagnostics of cancer diseases using highly automated processing of multidimensional biomedical images